Drugs / Rh-endostatin
Rh-endostatin
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00165373 | Jan 2003 → Jan 2005 | cancer | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06562673 | Dec 2024 → Apr 2025 | bone cancer, osteosarcoma | Shanghai 6th People's Hospital | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04094909 | Feb 2020 → Dec 2022 | — | Guangzhou Institute of Respiratory Disease | Unknown | No outcome recorded |
| Phase 2 | NCT03797625 | May 2017 → Dec 2020 | esophageal squamous cell carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT01529164 | Oct 2011 → Sep 2014 | colorectal cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02001168 | Oct 2013 → Dec 2020 | non-small cell lung carcinoma | Xinjiang Medical University | Unknown | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-07-28 | Jiangsu Simcere Pharmaceutical Co., Ltd. | COSELA® and Endostar® Receive Endorsement in Chinese Medical Association's Lung Cancer Treatment Guidelines simcere.com ↗ |
| 2022-06-07 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Latest Clinical Data regarding ENDOSTAR and Trilaciclib Presented at the 2022 ASCO simcere.com ↗ |
| 2021-05-26 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Simcere Will Announce Progress of Multiple Clinical Research on Antitumor Drugs at the 2021 ASCO Annual Meeting Endostar®（Recombinant Human Endostatin Injection） Envafolimab (KNO35) simcere.com ↗ |
| 2018-04-25 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Endostar included in CSCO Guidelines on the Diagnosis and Treatment simcere.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rh-endostatin | “Rh-Endostatin (Endostar; Simcere Pharmaceutical Co., Ltd, JiangSu,China) is a humanized recombinant endostatin” NCT01529164 ↗5“recombinant human endostatin (Rh-endostatin) plus irinotecan/cisplatin as second-line treatment” PMID 35380726 ↗ Apr 2022 |
| Known as | Endostar | “Intra-arterial Cisplatin Plus Anti-angiogenesis Inhibitor Rh-endostatin (Endostar) Combined With Systematic Chemotherapy in Osteosarcoma” NCT06562673 ↗ |
| Known as | recombinant human endostatin | “recombinant human endostatin (Rh-endostatin)” PMID 35380726 ↗ Apr 2022 |
| Action | Inhibit | “a direct angiogenesis inhibitor targeting the microvascular endothelial cells (ECs)” NCT01529164 ↗ |
| Modality | Protein / enzyme biologic | “rhEndostatin Protein” NCT00165373 ↗ |
| Route | Intravenous | “Administered by Continuous Intravenous Infusion” NCT00165373 ↗ |